近年来,作为率先获批上市的癌症免疫疗法,PD-1/PD-L1检查点抑制剂引领了癌症治疗的变革。因此,PD-1/PD-L1也成为国内外最热门的创新赛道。在PD-1的有利加持下,君实生物交出了2024年的业绩单。 3月27日晚间,君实生物(1877.HK,688180.SH)披露2024年度业绩显示,由于商业化药品销售收入持续增长,其2024全年实现营业收入19.48亿元,同比增长29.67%。其中...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.